MedTrace Logo

Impact of Covid-19 Pandemic on Patients Receiving Continuation or Maintenance Electroconvulsive Therapy

NCT05633368 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 47

Last updated 2022-12-01

No results posted yet for this study

Summary

Electroconvulsive therapy is a safe and effective therapeutic strategy in patients with treatment resistant depression. As relapse after successful ECT is significant even with adequate pharmacological strategies, continuation (up to 6 months after completion of index-ECT) or maintenance ECT (more than 6 months after index-ECT) is often necessary to maintain remission. During the current Covid-19 pandemic hospitals redirected resources and closed or significantly diminished ECT services. In this study we aim to assess the impact of discontinuing maintenance electroconvulsive therapy in patients diagnosed with unipolar depressive disorder.

Conditions

Interventions

OTHER

Questionnaires

Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse. * Patient Health Questionnaire (PHQ-9) * Clinical Global Impression (CGI) * Scaling question regarding depressive symptomatology

Sponsors & Collaborators

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Nele Van de Velde · University Hospital, Ghent

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2020-06-19
Completion
2020-06-19

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633368 on ClinicalTrials.gov